Recent Updates
Recently added Catalysts

Tarsus Pharmaceuticals, Inc.

TARSFDA catalysts, PDUFA dates & pipeline intelligence
$78.2
▼ -0.48 · -0.61%

Financials

Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Quarterly Cash
Unlock full TARS financials and dilution scoring
Quarter by quarter figures, cash trend and dilution risk.
Institutional-grade data · Cancel anytime
52W LOW $53.8952W HIGH $91.53
Volume
542.22 K
Value Traded
42.18 M
Short % Float
13%
Days to Cover
6.9
+1.88%Week
+12.52%1 Month
+6.48%3 Month
+20.7%6 Month
+95.17%5 Year
+284.32%All Time

Cash Data

Unlock TARS cash and runway
  • Monthly Burn
  • Burn Trend
  • Dilution Risk
  • SEC Filing

Key Stats

Market Cap
3.86 B
EPS (TTM)
-14.24
P/E Ratio
-
Ent. Value
3.62 B
Total Shares
49.31 M
Float Shares
46.65 M
Insiders
5.38%
Institutions
99.89%

Upcoming Catalysts

FDA decisions, readouts and PDUFA dates · scored by probability of approval

Catalyst Drug / Treatment Stage Prob. of Approval Description Drug Type Therapeutic Area Source
Phase 2 data readout
TP-05 (lotilaner)
Lyme disease prevention
Phase 2Small MoleculesInfectious Disease
Unlock every TARS catalyst date and PoA score
Every FDA decision, readout and PDUFA date, with drug type, therapeutic area and a PoA score you can trade on.
Institutional-grade data · Cancel anytime
PoA blends historical approval base rates, trial design score and FDA review track record.

TARS Catalyst Timeline

Dated clinical, regulatory and corporate events for Tarsus Pharmaceuticals, Inc.

Catalyst Timeline

Dated clinical, regulatory & corporate events for Tarsus Pharmaceuticals, Inc.

358Total events
18Upcoming
78Tier-1 (high impact)
2020 to 2029Coverage

Upcoming catalysts 2

T1Topline Readout
Subscribe to view catalyst details
TP-04
T2EU MAA Submission
Subscribe to view catalyst details
XdemvyApproved

Event history 50

▲Quarterly UpdateXdemvyApprovedCorporate
Tarsus reports Q3 2026 financial results with record XDEMVY net product sales of $194.6 million
Demodex blepharitissource ↗
●Management ChangeCorporate
Neera Clase appointed Chief Commercial Officer, effective Nov. 1, 2026
◆Oral PresentationPresentation
Paper: Assessment of Tea Tree-Based Management in Demodex Blepharitis: A Real-World Longitudinal Study
Demodex blepharitissource ↗
◆Poster PresentationXdemvyApprovedPresentation
Poster: Real-World Longitudinal Study of Patients with Demodex Blepharitis and Soft Contact Lens Wear in the United States: Interim Data Analysis
Demodex blepharitissource ↗
◆Poster PresentationTP-05ApprovedPresentation
Poster: Efficacy of Lotilaner 0.25% and Tea Tree Oil in Demodex Blepharitis: A Systematic Review and Meta-analysis
Demodex blepharitissource ↗
◆Poster PresentationPresentation
Poster: Real-World Longitudinal Study of Patients with Demodex Blepharitis in the United States: 9-Month Follow-up Findings
Demodex blepharitissource ↗
◆Poster PresentationPresentation
Poster: Real-World Patient-Reported Satisfaction and Factors Associated with Perceived Benefit of Lotilaner Ophthalmic Solution, 0.25% for Demodex Blepharitis
Demodex blepharitissource ↗
▲AcquiredCorporate
Tarsus completes acquisition of Alkeus Pharmaceuticals
●Quarterly UpdateCorporate
Q2 2026 financial results and corporate update webcast
▼Equity OfferingCorporate
Oversubscribed $125.0 million private placement equity financing announced
Unlock the full TARS catalyst timeline
Every PDUFA date, readout, approval and corporate move, tiered by market impact and updated daily.
Institutional-grade data · Cancel anytime

Past FDA Catalysts and PDUFA Decisions

How TARS actually traded into and out of each decision

Date Drug Catalyst Stage Reaction Event Move % Best Trade %
2023-12-31TP-03 (Ersa) Phase 2a topline data readout Phase 2a
Unlock 4 more TARS historical catalysts
Institutional-grade data · Cancel anytime
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision

Drug Pipeline Intelligence

Pipeline Score
Pipeline Value
Commercial Value
Valuation Signal
4
Drugs Scored
rNPV / MCap
Top Drug
Top 10%
Small Cap
(rank 73 of 725)
Percentile Rank
Commercial products (revenue basis: trailing 4 quarters of total revenue (10-K and 10-Q), to Sep 2026; product lines: last four quarters to Sep 2026 (10-K and 10-Q))
ProductRevenuePrior periodChange
XDEMVY
Showing 7 of 7 assets
DrugIndicationPhasePTRSrNPVStatusEnrollVelocityDesignEst. CompletionML SignalLast Change
TP-06 Small MoleculesNCT07886268Persistent Corneal Epithelial DefectPhase 2 RECRUITING 32Jul 7, 2028
TP-05 Small MoleculesNCT07562087Lyme DiseasePhase 2 ACTIVE NOT_RECRUITING 722Dec 1, 2027
Lotilaner, 2.0% Small MoleculesNCT07443202Ocular RosaceaPhase 2 ENROLLING BY_INVITATION 155Dec 31, 2027
IRX-101 Medical DevicesNCT05747430Retinal DiseasePhase 3 COMPLETED 395Mar 31, 2026
Lotilaner, 2.0% Small MoleculesNot countedNCT05838170Papulopustular RosaceaPhase 2 COMPLETED 37Nov 13, 2023
Xdemvy Small MoleculesMarketedNCT04784091BlepharitisApproved COMPLETED 833May 9, 2022
Xdemvy Small MoleculesNot countedNCT05454956Meibomian Gland DysfunctionPhase 2 COMPLETED 39May 18, 2023
Unlock the TARS pipeline intelligence model
PTRS, rNPV, enrollment velocity, trial design quality and ML risk signals for every asset above.
Institutional-grade data · Cancel anytime

Clinical Trial Results

Readouts, endpoints and source filings for every TARS program

Drug Name Indication Phase Date Trial Results SummaryTitleSource
TP-05 Lyme disease preventionPhase 2a2024-02-22Day 1: high dose mortality 97.0%, low dose mortality 92.0%, placebo mortality 5.0%; Day 30: high dose mortality 89.0%, low dose mortality 91.0%, placebo mortality 9.0%Read MoreTarsus Announces Positive Topline Results from Carpo, a Phase 2a Proof-of-Concept “Tick-Kill” Trial Evaluating TP-05 (lotilaner) for the Prevention of Lyme DiseaseRead More
Scroll for more · summaries link to the source press release
Unlock every TARS trial readout
Institutional-grade data · Cancel anytime

Inside Trades

Unlock TARS insider buying and selling
Monthly insider buys and sells against the stock price, with the insider sentiment reading.
Institutional-grade data · Cancel anytime
InsiderSideSharesPriceValueDate
Azamian Bobak R.Director, Officer (President/CEO and Board Chair)Sell -10,000 817,991 held$80.31 11/13/2026
Unlock the full TARS insider trade log
Institutional-grade data · Cancel anytime

Hedge Fund 13F Activity

Fund % of Portfolio Current MV Shares Owned Activity
Deep Track Capital, LP 4.9 % (44.1 %) 299.25 M 3.81 M 3.82% ( 140.00 K)
Unlock every fund holding TARS
Every 13F position with quarter over quarter share flow and average entry price.
Institutional-grade data · Cancel anytime
Unlock hedge fund flows in TARS
Shares held by hedge funds each quarter, and who bought or sold.

Ownership Trends

Sign in to see TARS ownership
Insider and institutional ownership, quarter by quarter.

TARS Short Interest

Shares sold short, counted twice a month.

13%
Short % of Float
of tradable shares sold short
6.1M
Shares Sold Short
+5.8% vs prior count
6.9 High
Days to Cover
trading days of normal volume to buy every short share back
874.5K
Avg Daily Volume
the average used for days to cover
Unlock TARS short interest history
Two years of days to cover and shares sold short, with every count and its change.
Institutional-grade data · Cancel anytime

Options Data

Option Volume

Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg

Option Chain Statistics

ExpiryCall VolPut VolVol P/CCall OIPut OIOI P/CIV CallIV Call OI-WtdIV Call Vol-WtdIV PutIV Put OI-WtdIV Put Vol-Wtd
2026-11-20
Unlock TARS option chain statistics
Per-expiry call and put volume, open interest, put-call ratios and implied volatility.
Institutional-grade data · Cancel anytime

Real-Time Option Chain

CallsStrikePuts
LastVolOILastVolOI
No data available
Unlock the live TARS option chain
Live calls and puts by strike: last price, volume and open interest for every expiry.
Institutional-grade data · Cancel anytime

Calls vs Puts by Expiry

CallsPutsLog scale
Unlock TARS options analytics
Institutional-grade data · Cancel anytime

Competitive positioning

How TARS ranks across every disease it competes in

Competitive Position is a premium feature
See how TARS ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial

TARS News

TARS
Nov 5, 2026
TARSConferences/Events

Tarsus to Participate in Upcoming Investor Conferences

Tarsus Pharmaceuticals announced its participation in several upcoming investor conferences. Notable events include the Guggenheim 3rd Annual Healthcare Conference on November 10th and the Jefferies Global Healthcare Conference on November 18th and 19th. Management will also engage in a fireside chat at the Piper Sandler Conference on December 1st.

Read more →
TARS
Nov 3, 2026
TARSGeneral

Tarsus Reports Third Quarter 2026 Financial Results

Tarsus Pharmaceuticals reported record net product sales of $194.6 million for Q3 2026, marking a 64% increase year-over-year. The company surpassed one million bottles of XDEMVY dispensed and achieved over $1 billion in cumulative sales. Despite these successes, Tarsus faced a net loss of $668.3 million, largely due to increased R&D and SG&A expenses.

Read more →
TARS
Oct 29, 2026
TARSConferences/Events

Tarsus to Report Third Quarter 2026 Financial Results on Tuesday, November 3, 2026

Tarsus Pharmaceuticals will host a live webcast on November 3, 2026, to report its third quarter 2026 financial results and provide a corporate update. The company is advancing its pipeline, including treatments for ocular rosacea and Lyme disease. XDEMVY is already FDA approved for treating Demodex blepharitis.

Read more →
TARS
Oct 28, 2026
TARSGeneral

Tarsus Pharmaceuticals Appoints Neera Clase as Chief Commercial Officer

Tarsus Pharmaceuticals announced the appointment of Neera Clase as Chief Commercial Officer, effective November 1, 2026. Clase, who has been with Tarsus since July 2026, will lead the commercial strategy focusing on expanding the reach of XDEMVY. She aims to leverage her experience to enhance Tarsus's pipeline, which includes several investigational treatments.

Read more →
TARS
Sep 29, 2026
TARSConferences/Events

Tarsus Plans to Present 11 Abstracts Highlighting New Insights in Demodex Blepharitis, Ocular Rosacea and the Real-World Impact of XDEMVY at the American Academy of Optometry 2026 Annual Meeting

Tarsus Pharmaceuticals plans to present 11 scientific abstracts at the American Academy of Optometry 2026 Annual Meeting, focusing on Demodex blepharitis, ocular rosacea, and the real-world impact of XDEMVY. These findings aim to enhance understanding and management of these conditions among eye care professionals. The conference will take place from September 30 to October 3 in Anaheim, California.

Read more →
TARS
Sep 4, 2026
TARSGeneral
▲ +9.1%on this news

Tarsus Pharmaceuticals Completes Acquisition of Alkeus Pharmaceuticals, Expanding Leadership in Eye Care

Tarsus Pharmaceuticals has completed its acquisition of Alkeus Pharmaceuticals, enhancing its focus on eye care. The acquisition adds ALK-001, an investigational treatment for Stargardt disease, which has received multiple FDA designations. Tarsus aims to advance the NORTHSTAR Phase 3 trial for ALK-001, with topline data expected in 2029.

Read more →
TARS
Aug 6, 2026
TARSGeneral
▲ +6.6%on this news

Tarsus Reports Second Quarter 2026 Financial Results, Advances Next Phase of Growth

Tarsus reported strong financial results for the second quarter of 2026, with net product sales of $173.9 million, reflecting a 69% increase year-over-year. The company has raised its full-year sales guidance to between $685 million and $705 million. Additionally, Tarsus is pursuing the acquisition of Alkeus Pharmaceuticals to further develop its retina pipeline, which includes a Phase 3 study.

Read more →
TARS
Aug 6, 2026
TARSGeneral
▲ +6.6%on this newsshared move

Tarsus Pharmaceuticals Announces Oversubscribed $125.0 Million Private Placement Equity Financing

Tarsus Pharmaceuticals has announced a successful $125 million private placement equity financing. The deal includes participation from existing and new investors, aimed at funding clinical development and other corporate purposes. The financing is set to close on August 7, 2026, subject to customary conditions.

Read more →
TARS
Aug 6, 2026
TARSGeneral
▲ +6.6%on this newsshared move

Tarsus Pharmaceuticals to Acquire Alkeus Pharmaceuticals and Advance Eye Care Leadership Position

Tarsus Pharmaceuticals has announced its acquisition of Alkeus Pharmaceuticals, focusing on gildeuretinol (ALK-001), an investigational oral therapy for Stargardt disease. This acquisition aims to enhance Tarsus' position in the retina market and is backed by positive clinical findings. The deal includes a $450 million upfront payment and potential future milestones. Top-line data from the Phase 3 NORTHSTAR trial is expected in 2029.

Read more →
TARS
Aug 6, 2026
TARSGeneral
▲ +6.6%on this newsshared move

Tarsus to Report Second Quarter 2026 Financial Results on Thursday, August 6, 2026

Tarsus Pharmaceuticals will report its second quarter 2026 financial results on August 6, 2026. The company will host a live webcast at 5:00 a.m. PT to provide updates. Tarsus focuses on innovative treatments in eye care and other therapeutic areas, with products in various stages of development.

Read more →
TARS
Jul 13, 2026
TARSGeneral
▼ -5.4%on this news

Tarsus Pharmaceuticals Announces Executive Leadership Transition as Company Advances Next Phase of Growth

Tarsus Pharmaceuticals announced the departure of Chief Commercial Officer Aziz Mottiwala, who will become CEO of a medical device company. Neera Clase has been appointed as Interim Chief Commercial Officer. This transition occurs as Tarsus enters a growth phase following the successful launch of XDEMVY and the acquisition of iRenix Medical, strengthening its position in eye care.

Read more →
TARS
Jul 8, 2026
TARSGeneral
▼ -5.3%on this news· ran to -17% by day 3shared move

Tarsus Advances Eye Care Leadership Strategy with Acquisition of iRenix Medical and Late-Stage Asset IRX-101

Tarsus Pharmaceuticals agreed to acquire iRenix Medical for an upfront payment of approximately $75 million. The deal includes potential milestone payments of up to $490 million. Tarsus will advance the late-stage asset IRX-101 through a Phase 3 study starting in 2027. The company plans to announce results from this trial in 2028.

Read more →
TARS
May 29, 2026
TARSConferences/Events

Tarsus to Participate in Upcoming June 2026 Investor Conferences

Tarsus Pharmaceuticals, Inc. announced its participation in several upcoming investor conferences in June 2026. The company aims to showcase its advancements in eye care and infectious disease prevention. Tarsus is also progressing its pipeline, including FDA-approved XDEMVY and other treatments in Phase 2 development.

Read more →
TARS
May 14, 2026
TARSGeneral

Tarsus and John Cena Partner to Raise Awareness of Demodex blepharitis, a Common Eyelid Disease Affecting Approximately 25 Million Americans

Tarsus Pharmaceuticals has partnered with John Cena to raise awareness about Demodex blepharitis, a common eyelid disease affecting around 25 million Americans. Cena shares his personal experience with the condition and the FDA-approved treatment, XDEMVY. The campaign aims to encourage individuals to prioritize their eye health and seek proper diagnosis and treatment.

Read more →
TARS
May 8, 2026
TARSConferences/Events

Tarsus to Participate in Upcoming May 2026 Investor Conferences

Tarsus Pharmaceuticals, Inc. has announced its participation in upcoming investor conferences. The company is focused on advancing its pipeline, which includes FDA-approved XDEMVY for Demodex blepharitis and other treatments in development. These efforts highlight Tarsus's commitment to addressing high unmet needs in eye care and infectious disease prevention.

Read more →
TARS
May 7, 2026
TARSFDA Updates

Tarsus Reports First Quarter 2026 Financial Results and Recent Business Achievements

Tarsus Pharmaceuticals reported strong first quarter 2026 financial results, with XDEMVY sales exceeding $145 million, marking an 85% increase year-over-year. The company reaffirmed its full-year sales guidance of $670-700 million and highlighted the growing adoption of XDEMVY among eye care professionals. Additionally, Tarsus initiated a Phase 2 trial for TP-05, an investigational oral tablet aimed at preventing Lyme disease.

Read more →
TARS
Apr 29, 2026
TARSGeneral

Tarsus to Report First Quarter 2026 Financial Results on Wednesday, May 6, 2026

Tarsus Pharmaceuticals, Inc. will host a live webcast on May 6, 2026, to report its first quarter financial results and provide a corporate update. The company is focused on innovative treatments in eye care and infectious disease prevention. Tarsus has FDA approval for its product XDEMVY and is developing additional therapies in Phase 2.

Read more →

About Tarsus Pharmaceuticals, Inc.

Irvine, CA 370 employees tarsusrx.com
Headquarters15440 LAGUNA CANYON ROAD, IRVINE, CA, 92618
BIOPHARMAWATCH ELITE
Trade the next TARS catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $24/mo billed annually.
Cancel anytime